Claritin joins the $1 bil. club
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough says sales of the allergy drug have surpassed $1 bil. since moving over the counter at the end of 2002. The success of the antihistamine "solidifies" Schering's "long-standing leadership position" in the Rx-to-OTC switch arena, the firm claims in a March 22 statement...
You may also be interested in...
A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date
Schering Prepares For “Turnaround”; Claritin Falls Flat In First Quarter
Schering-Plough's Claritin experienced another relatively flat quarter despite an increase in promotional spending
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.